A REVIEW ON DENGUE AND ITS INHIBITORS
The worldwide occurrence of infectious virus diseases represents a huge danger to public health. One of the most remarkable of these infections is the Dengue virus (DENV) infection. Around 400 million persons are infected yearly, as per a WHO survey; symptoms escalate in about one-quarter of cases. Both academic and industrial researchers have performed various basic and clinical studies on virus epidemiology, structure and function analysis, cause and path of infection, therapeutic targets, vaccines, and therapeutic drugs. Currently, the only licensed vaccine is CYD-TDV or Dengvaxia, but potent inhibitors are currently under production. This analysis provides a summary of the virus life cycle and the history of DENVs, and reflects on and summarises the most recently identified antiviral candidates and newly found promising targets. We agree that these advances and shortcomings have provided for progress in the discovery of anti-DENV drugs and hope that our analysis can encourage more research in this field.